Please use this identifier to cite or link to this item:
Title: Health policies to control Chagas disease transmission in European countries
Author: Requena-Méndez, Ana
Albajar Viñas, Pere
Angheben, Andrea
Chiodini, Peter L.
Gascón i Brustenga, Joaquim
Muñoz, José
Chagas Disease COHEMI Working Group
Keywords: Malaltia de Chagas
Insectes paràsits
Chagas' disease
Parasitic insects
Issue Date: 30-Oct-2014
Publisher: Public Library of Science (PLoS)
Abstract: Chagas disease (CD) is a highly prevalent parasitic disease in immigrants from Mexico, as well as all of Central and South America. The total number of infected people is estimated between eight and ten million [1], [2], of whom 30%-40% either have, or will, develop cardiopathy, gastrointestinal disease, or both [1]. Cardiac involvement is the main cause of death from this infection through arrhythmias and cardiomyopathy. Nifurtimox and benznidazole are the only available medicines with proven efficacy against Trypanosoma cruzi infection in acute, congenital infection and early chronic infection. Until recently the treatment of chronic disease, particularly of adult patients with indeterminate form, was controversial; but during the past decade there has been a trend to offer treatment to adult patients and those with early cardiomyopathy.
Note: Reproducció del document publicat a:
It is part of: PLoS Neglected Tropical Diseases, 2014, vol. 8, num. 10, p. e3245
Related resource:
ISSN: 1935-2735
Appears in Collections:Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
679535.pdf811.72 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons